Helge C. Dorfmueller

Dr. Helge C. Dorfmueller

School of Life Sciences, University of Dundee, Dundee, Scotland, UK

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2006 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
FRFrancesco V Rao
Francesco V Rao
HDHelge C. Dorfmueller
Helge C. Dorfmueller
FVFabrizio Villa
Fabrizio Villa
MAMatthew Allwood
Matthew Allwood
IEIan Michael Eggleston
Ian Michael Eggleston
DADaan MF Van Aalten
Daan MF Van Aalten
O ‐linked N ‐acetylglucosamine ( O ‐GlcNAc) modification of specific serines/threonines on intracellular proteins in higher eukaryotes has been shown to directly regulate important processes such as the cell cycle, insulin sensitivity and transcription. The structure, molecular mechanisms of catalysis, protein substrate recognition/specificity of the eukaryotic O ‐GlcNAc transferase and hydrolase are largely unknown. Here we describe the crystal structure, enzymology and in vitro activity on human substrates of Clostridium perfringens NagJ, a close homologue of human O ‐GlcNAcase (OGA), representing the first family 84 glycoside hydrolase structure. The structure reveals a deep active site pocket highly conserved with the human enzyme, compatible with binding of O ‐GlcNAcylated peptides. Together with mutagenesis data, the structure supports a variant of the substrate‐assisted catalytic mechanism, involving two aspartic acids and an unusually positioned tyrosine. Insights into recognition of substrate come from a complex with the transition state mimic O ‐(2‐acetamido‐2‐deoxy‐d‐glucopyranosylidene)amino‐ N ‐phenylcarbamate ( K i=5.4 nM). Strikingly, the enzyme is inhibited by the pseudosubstrate peptide Ala‐Cys(‐ S ‐GlcNAc)‐Ala, and has OGA activity against O ‐GlcNAcylated human proteins, suggesting that the enzyme is a suitable model for further studies into the function of human OGA.

1 December 2006 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
HDHelge C. Dorfmueller
Helge C. Dorfmueller
VBVladimir S. Borodkin
Vladimir S. Borodkin
MSMarianne Schimpl
Marianne Schimpl
SSSharon M. Shepherd
Sharon M. Shepherd
NSNatalia A. Shpiro
Natalia A. Shpiro
DADaan MF Van Aalten
Daan MF Van Aalten

1 December 2020 in The Cell Surface
Verified
Journal Article
Open access
MLMegan Lenardon
Megan Lenardon
PSPrashant Sood
Prashant Sood
HDHelge C. Dorfmueller
Helge C. Dorfmueller
ABAlistair J.P. Brown
Alistair J.P. Brown
NGNeil Gow
Neil Gow
• In wild type C. albicans yeast cells grown in standard lab conditions: • Chitin microfibrils are interspersed throughout the inner layer of the cell wall. • Cell wall proteins are embedded throughout the inner layer of the cell wall. • The outer fibrillar layer represents N-mannan outer chains. • The length of fibrils correlates with the length of the α(1,6)-N-mannan backbone. • Side chains extend from the α(1,6)-backbone at fixed angles every 10 mannose residues.

10 March 2021 in Royal Society Open Science
Verified
Journal Article
Open access
SCSowmya Ajay Castro
Sowmya Ajay Castro
HDHelge C. Dorfmueller
Helge C. Dorfmueller
Streptococcus pyogenes, also known as Group A Streptococcus (GAS), is a Gram-positive human-exclusive pathogen, responsible for more than 500 000 deaths annually worldwide. Upon infection, GAS commonly triggers mild symptoms such as pharyngitis, pyoderma and fever. However, recurrent infections or prolonged exposure to GAS might lead to life-threatening conditions. Necrotizing fasciitis, streptococcal toxic shock syndrome and post-immune mediated diseases, such as poststreptococcal glomerulonephritis, acute rheumatic fever and rheumatic heart disease, contribute to very high mortality rates in non-industrialized countries. Though an initial reduction in GAS infections was observed in high-income countries, global outbreaks of GAS, causing rheumatic fever and acute poststreptococcal glomerulonephritis, have been reported over the last decade. At the same time, our understanding of GAS pathogenesis and transmission has vastly increased, with detailed insight into the various stages of infection, beginning with adhesion, colonization and evasion of the host immune system. Despite deeper knowledge of the impact of GAS on the human body, the development of a successful vaccine for prophylaxis of GAS remains outstanding. In this review, we discuss the challenges involved in identifying a universal GAS vaccine and describe several potential vaccine candidates that we believe warrant pursuit.

13 May 2009 in Biochemical Journal
Verified
Journal Article
Open access
HDHelge C. Dorfmueller
Helge C. Dorfmueller
VBVladimir S. Borodkin
Vladimir S. Borodkin
MSMarianne Schimpl
Marianne Schimpl
DADaan MF Van Aalten
Daan MF Van Aalten
O-GlcNAcylation is an essential, dynamic and inducible post-translational glycosylation of cytosolic proteins in metazoa and can show interplay with protein phosphorylation. Inhibition of OGA (O-GlcNAcase), the enzyme that removes O-GlcNAc from O-GlcNAcylated proteins, is a useful strategy to probe the role of this modification in a range of cellular processes. In the present study, we report the rational design and evaluation of GlcNAcstatins, a family of potent, competitive and selective inhibitors of human OGA. Kinetic experiments with recombinant human OGA reveal that the GlcNAcstatins are the most potent human OGA inhibitors reported to date, inhibiting the enzyme in the sub-nanomolar to nanomolar range. Modification of the GlcNAcstatin N-acetyl group leads to up to 160-fold selectivity against the human lysosomal hexosaminidases which employ a similar substrate-assisted catalytic mechanism. Mutagenesis studies in a bacterial OGA, guided by the structure of a GlcNAcstatin complex, provides insight into the role of conserved residues in the human OGA active site. GlcNAcstatins are cell-permeant and, at low nanomolar concentrations, effectively modulate intracellular O-GlcNAc levels through inhibition of OGA, in a range of human cell lines. Thus these compounds are potent selective tools to study the cell biology of O-GlcNAc.

17 July 2010 in Amino Acids
Verified
Journal Article
Open access
PDF file
HDHelge C. Dorfmueller
Helge C. Dorfmueller
VBVladimir S. Borodkin
Vladimir S. Borodkin
DBDavid E. Blair
David E. Blair
SPShalini Pathak
Shalini Pathak
INIva Navratilova
Iva Navratilova
DADaan MF Van Aalten
Daan MF Van Aalten
Protein glycosylation on serine/threonine residues with N-acetylglucosamine (O-GlcNAc) is a dynamic, inducible and abundant post-translational modification. It is thought to regulate many cellular processes and there are examples of interplay between O-GlcNAc and protein phosphorylation. In metazoa, a single, highly conserved and essential gene encodes the O-GlcNAc transferase (OGT) that transfers GlcNAc onto substrate proteins using UDP–GlcNAc as the sugar donor. Specific inhibitors of human OGT would be useful tools to probe the role of this post-translational modification in regulating processes in the living cell. Here, we describe the synthesis of novel UDP–GlcNAc/UDP analogues and evaluate their inhibitory properties and structural binding modes in vitro alongside alloxan, a previously reported weak OGT inhibitor. While the novel analogues are not active on living cells, they inhibit the enzyme in the micromolar range and together with the structural data provide useful templates for further optimisation.